ReviewPharmacoEconomics2009
Cost effectiveness of influenza vaccination in older adults: a critical review of economic evaluations for the 50- to 64-year age group.
Review in PharmacoEconomics, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Acute myocardial infarction and influenza: a meta-analysis of case-control studies.Heart (British Cardiac Society) · 2015Pooled it
- Uptake and correlates of influenza vaccine among older adults residing in rural regions of south China: a cross-sectional study.Frontiers in public health · 2024Article
- Article
- Application of Dendrimers for the Treatment of Infectious Diseases.Molecules (Basel, Switzerland) · 2018Review
- WHO guide on the economic evaluation of influenza vaccination.Influenza and other respiratory viruses · 2018Review
- Article
- Ischaemic heart disease, influenza and influenza vaccination: a prospective case control study.Heart (British Cardiac Society) · 2013Article
- Review
- Key issues for estimating the impact and cost-effectiveness of seasonal influenza vaccination strategies.Human vaccines & immunotherapeutics · 2013Review
- Economic evaluations of childhood influenza vaccination: a critical review.PharmacoEconomics · 2012Review
- Issues in the economic evaluation of influenza vaccination by injection of healthy working adults in the US: a review and decision analysis of ten published studies.PharmacoEconomics · 2012Review
- Implementing an influenza vaccination programme for adults aged ≥65 years in Poland: a cost-effectiveness analysis.Clinical drug investigation · 2012Article
- To model or not to model: lessons from two vaccinations.The European journal of health economics : HEPAC : health economics in prevention and care · 2011Article
- Iron-chelating therapies in a transfusion-dependent thalassaemia population in Thailand: a cost-effectiveness study.Clinical drug investigation · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Several recent studies have assessed the benefits of extending influenza vaccination programmes, which are currently targeted primarily at those aged over 65 years, to those aged 50-64 years. We identified and reviewed all cost-effectiveness studies of influenza vaccination in those aged 50-64 years published before July 2008. While the studies suggest that vaccination in this age-group is likely to be cost effective, these results were dependent on several key assumptions. The estimates of serious outcomes due to influenza and the estimates of vaccine effectiveness (VE) against these outcomes were found to have the most influence on cost effectiveness. However, due to factors including mismatches between the measure of VE and the outcome under consideration, as well as various other data limitations, there is significant uncertainty around these key assumptions that was not well explored. There was a failure in some studies to report fundamental inputs such as discount rates. Overall, there was a general lack of transparency in the studies and, consequently, the conclusions around the cost effectiveness of influenza vaccine in those aged 50-64 years must be interpreted with caution.
Indexed as
Identifiers
19640008What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.